Dose Finding and Food Effect Studies of a Novel Abiraterone Acetate Formulation for Oral Suspension in Comparison to a Reference Formulation in Healthy Male Subjects

Currently approved formulations of the androgen synthesis inhibitor abiraterone acetate (AA) consist of multiple tablets administered daily in a fasted state. Removing the food effect and switching to a suspension formulation is expected to improve the pharmacokinetic profile and facilitate drug administration for patients with late-stage prostate cancer. Two four-sequence, four-period randomized crossover investigations were undertaken to establish the pharmacokinetic profiles of single doses of commercially available Zytiga®, as the reference AA (R-AA), and a novel tablet for oral suspension (TOS). Four single doses of TOS (from 62.5 to 250 mg) were compared in study C01, and two single doses each of TOS (250 mg) and R-AA (1000 mg) were compared under fasted and fed (modified fasted for R-AA) conditions in C02. Plasma concentrations of abiraterone over time were measured, and pharmacokinetic parameters were calculated. Each doubling of the dose of TOS was associated with a greater than 3-fold increase in exposure. A single dose of TOS (250 mg) exhibited similar exposure over 24 h, whether given fasted (625 ng × h/mL) or fed (485 ng × h/mL). A single dose of TOS (250 mg) was associated with higher (fasted, p = 0.028) or equivalent exposure (fed) compared to 1000 mg R-AA fasted (532 ng × h/mL). Substantially higher exposures were seen with 1000 mg R-AA under modified fasted conditions compared to TOS, irrespective of prandial status (p < 0.001). TOS was generally safe and well tolerated in the study. A 250 mg dose of a novel AA formulation for oral suspension demonstrated bioequivalence to 1000 mg R-AA under fasted conditions. This novel TOS formulation also addresses some of the limitations of current AA treatment, including low bioavailability, high variability in systemic exposure and a large food effect. It may offer an alternative for patients with dysphagia or discomfort with swallowing large pills.

[1]  C. Prestidge,et al.  Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. , 2020, International journal of pharmaceutics.

[2]  D. Walsh,et al.  Dysphagia prevalence and predictors in cancers outside the head, neck, and upper gastrointestinal tract. , 2019, Journal of pain and symptom management.

[3]  T. Solymosi,et al.  Investigations of the mechanism behind the rapid absorption of nano‐amorphous abiraterone acetate , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  C. Stein,et al.  The Effect of Food on the Absorption of Abiraterone Acetate from a Fine Particle Dosage Form: A Randomized Crossover Trial in Healthy Volunteers , 2017, Oncology and Therapy.

[5]  K. Zejnullahu,et al.  High‐Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer , 2017, Clinical genitourinary cancer.

[6]  L. Molnár,et al.  Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements. , 2017, International journal of pharmaceutics.

[7]  H. Wakabayashi,et al.  Prevalence of sarcopenia and its association with dysphagia in cancer patients who require rehabilitation. , 2017, Journal of rehabilitation medicine.

[8]  L. Molnár,et al.  Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect , 2017, Cancer Chemotherapy and Pharmacology.

[9]  R. Goldwater,et al.  Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies , 2017, Clinical Pharmacokinetics.

[10]  C. Kollmannsberger,et al.  Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer , 2015, Journal of clinical pharmacology.

[11]  J. Go,et al.  Pill Properties that Cause Dysphagia and Treatment Failure , 2015, Current therapeutic research, clinical and experimental.

[12]  R. DiPaola,et al.  Abiraterone in Prostate Cancer: A New Angle to an Old Problem , 2012, Clinical Cancer Research.

[13]  Blair K. Brettmann,et al.  Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. , 2007, Molecular pharmaceutics.